Trials / Completed
CompletedNCT02834936
A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation
A Phase 2 Clinica Study: Efficacy and Safety of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to evaluate the efficacy and safety of Pyrotinib in patients of advanced pre-treated Non-small cell lung cancer With HER2 Mutation. To observe objective response rate (ORR) of pyrotinib in NSCLC With HER2 Mutation. To observe Progression free survival (PFS). To assess the overall survival (OS). A secondary aim is to obtain safety information. To explore the relationship between biomarkers and the toxicity/efficacy of Pyrotinib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pyrotinib |
Timeline
- Start date
- 2016-10-20
- Primary completion
- 2019-06-20
- Completion
- 2019-06-20
- First posted
- 2016-07-15
- Last updated
- 2025-08-28
Locations
11 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02834936. Inclusion in this directory is not an endorsement.